Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $398,019 | -64.4% | 73,031 | -55.7% | 0.00% | -66.7% |
| Q2 2023 | $1,118,815 | +43.5% | 164,774 | +5.9% | 0.00% | +50.0% |
| Q1 2023 | $779,691 | -23.7% | 155,627 | -25.7% | 0.00% | -33.3% |
| Q4 2022 | $1,022,194 | +62.5% | 209,466 | +440.0% | 0.00% | +200.0% |
| Q4 2021 | $629,000 | -59.8% | 38,792 | -16.1% | 0.00% | -75.0% |
| Q2 2021 | $1,563,000 | -81.2% | 46,228 | -83.1% | 0.00% | -81.8% |
| Q1 2021 | $8,292,000 | +111.4% | 274,217 | +246.1% | 0.02% | +100.0% |
| Q4 2020 | $3,923,000 | +10.5% | 79,242 | -14.3% | 0.01% | -15.4% |
| Q3 2020 | $3,551,000 | -44.3% | 92,499 | -37.4% | 0.01% | -59.4% |
| Q2 2020 | $6,380,000 | +102.4% | 147,675 | +22.3% | 0.03% | +23.1% |
| Q1 2020 | $3,152,000 | -41.5% | 120,780 | -29.9% | 0.03% | +62.5% |
| Q4 2019 | $5,386,000 | +1654.4% | 172,337 | +1363.6% | 0.02% | +1500.0% |
| Q3 2019 | $307,000 | – | 11,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |